Open Payments

FRED ELIAS GHALI

Type
Physician · Allopathic & Osteopathic Physicians / Dermatology
Where
GRAPEVINE, TX
NPI
1639286339
Received
$630,893 in 1,395 records, 2019 to 2025 ($623,953 general, $6,940 research)
As principal investigator
$283,822 of research payments to others in 170 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment297$130,856
2024General payment227$94,279
2023General payment242$81,061
2023Research payment1$2,700
2022General payment214$67,942
2021General payment92$37,073
2021Research payment2$3,540
2020General payment147$95,872
2019General payment171$116,866
2019Research payment2$700

By company

CompanyRecordsAmountYears
GENZYME CORPORATION317$250,2382019–2025
Regeneron Healthcare Solutions, Inc.259$156,4452019–2025
SANOFI-AVENTIS U.S. LLC14$48,5462019–2020
Galderma Laboratories, L.P.103$42,7172019–2025
Incyte Corporation74$30,5692021–2025
Dermavant Sciences, Inc.23$25,9782023–2024
Organon Llc31$12,6782025
Regeneron Pharmaceuticals, Inc.14$11,0052019–2022
Novartis Pharmaceuticals Corporation10$9,8312020–2022
Arcutis Biotherapeutics, Inc.42$9,7792023–2025
ABBVIE INC.108$7,5802019–2025
Almirall LLC26$5,9332019–2025
PFIZER INC.61$4,7022022–2025
EPI Health, LLC6$3,7562019
Eli Lilly and Company1$2,7002023
Janssen Biotech, Inc.3$1,9852025
Verrica Pharmaceuticals Inc.2$1,2172023
Lilly USA, LLC42$9892020–2025
MAYNE PHARMA COMMERCIAL LLC123$9632019–2025
Ortho Dermatologics, a division of Bausch Health US, LLC62$8712020–2025
LEO Pharma AS2$7002019
SUN PHARMACEUTICAL INDUSTRIES INC.28$6482019–2024
Krystal Biotech Inc13$2702023–2025
Amgen Inc.7$2412019–2025
LEO Pharma Inc.4$892022–2024
LNHC, Inc4$692025
Celgene Corporation1$562019
NOBELPHARMA AMERICA, LLC3$492023–2025
Allergan, Inc.1$472019
Biofrontera Inc.2$452019
DERMIRA, INC.2$302019
Botanix SB Inc1$282025
Alexion Pharmaceuticals, Inc.1$252022
Medimetriks Pharmaceuticals, Inc.1$242020
Journey Medical Corporation1$212022
Janssen Scientific Affairs, LLC1$202025
Cipher Pharmaceuticals US LLC1$182025
Mylan Pharmaceuticals Inc.1$152019

By nature of payment

NatureRecordsAmount
Compensation for services other than consulting, including serving as faculty or as a speaker at a v118$404,978
Consulting Fee40$139,658
Travel and Lodging151$37,669
Food and Beverage1,072$28,010
Honoraria4$13,400
Research payment5$6,940
Education5$235

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-23Incyte Corporation$7,335Consulting FeeCash or cash equivalentOpzelura Drug, Dermatology2025
2025-12-23Incyte Corporation$4,890Consulting FeeCash or cash equivalentOpzelura Drug, Dermatology2025
2025-12-19Regeneron Healthcare Solutions, Inc.$13Travel and LodgingIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-12-15GENZYME CORPORATION$31Food and BeverageIn-kind items and servicesDUPIXENT Biological, Immunology2025
2025-12-11Regeneron Healthcare Solutions, Inc.$27Food and BeverageIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-12-09Ortho Dermatologics, a division of Bausch Health US, LLC$19Food and BeverageIn-kind items and servicesCabtreo Drug, Dermatology2025
2025-12-04Incyte Corporation$20Food and BeverageCash or cash equivalentOpzelura Drug, Dermatology2025
2025-12-04Incyte Corporation$19Food and BeverageCash or cash equivalentOpzelura Drug, Dermatology2025
2025-12-03Incyte Corporation$811Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-12-03Incyte Corporation$438Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-12-03Incyte Corporation$61Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-12-03ABBVIE INC.$29Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-12-01Organon Llc$23Food and BeverageIn-kind items and services2025
2025-11-28Organon Llc$254Travel and LodgingIn-kind items and servicesVTAMA Drug, Dermatology2025
2025-11-25GENZYME CORPORATION$29Food and BeverageIn-kind items and servicesDUPIXENT Biological, Immunology2025
2025-11-24Arcutis Biotherapeutics, Inc.$23Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2025
2025-11-21GENZYME CORPORATION$5,551Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDUPIXENT Biological, Immunology2025
2025-11-21Regeneron Healthcare Solutions, Inc.$4,697Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-11-21GENZYME CORPORATION$42Travel and LodgingCash or cash equivalentDUPIXENT Biological, Immunology2025
2025-11-20Regeneron Healthcare Solutions, Inc.$15Food and BeverageIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-11-19Incyte Corporation$19Food and BeverageCash or cash equivalentOPZELURA Drug, Dermatology2025
2025-11-18Regeneron Healthcare Solutions, Inc.$28Food and BeverageIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-11-18MAYNE PHARMA COMMERCIAL LLC$1Food and BeverageIn-kind items and services2025
2025-11-17MAYNE PHARMA COMMERCIAL LLC$7Food and BeverageIn-kind items and services2025
2025-11-17Arcutis Biotherapeutics, Inc.$3Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2025
2025-11-13PFIZER INC.$20Food and BeverageIn-kind items and servicesCIBINQO Drug, Inflammation & Immunology2025
2025-11-12Regeneron Healthcare Solutions, Inc.$29Food and BeverageIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-11-12LNHC, Inc$18Food and BeverageIn-kind items and servicesZELSUVMI Drug, DERMATOLOGY2025
2025-11-12Arcutis Biotherapeutics, Inc.$17Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2025
2025-11-08Galderma Laboratories, L.P.$6Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-11-06Incyte Corporation$22Food and BeverageCash or cash equivalentOPZELURA Drug, Dermatology2025
2025-11-04Incyte Corporation$7,312Consulting FeeCash or cash equivalentOPZELURA Drug, Dermatology2025
2025-11-04Incyte Corporation$247Consulting FeeCash or cash equivalentOPZELURA Drug, Dermatology2025
2025-11-04PFIZER INC.$17Food and BeverageIn-kind items and servicesCIBINQO Drug, Inflammation & Immunology2025
2025-11-03Arcutis Biotherapeutics, Inc.$18Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2025
2025-10-30Regeneron Healthcare Solutions, Inc.$34Food and BeverageIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-10-30Ortho Dermatologics, a division of Bausch Health US, LLC$21Food and BeverageIn-kind items and servicesCabtreo Drug, Dermatology2025
2025-10-30Ortho Dermatologics, a division of Bausch Health US, LLC$17Food and BeverageIn-kind items and servicesCabtreo Drug, Dermatology2025
2025-10-28ABBVIE INC.$24Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-10-24Regeneron Healthcare Solutions, Inc.$2,135Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-10-24Incyte Corporation$21Food and BeverageCash or cash equivalentOPZELURA Drug, Dermatology2025
2025-10-24Janssen Scientific Affairs, LLC$20Food and BeverageIn-kind items and servicesTREMFYA Drug, Immunology2025
2025-10-23Galderma Laboratories, L.P.$13Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-10-21ABBVIE INC.$11Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-10-21MAYNE PHARMA COMMERCIAL LLC$1Food and BeverageIn-kind items and services2025
2025-10-20GENZYME CORPORATION$29Food and BeverageIn-kind items and servicesDUPIXENT Biological, Immunology2025
2025-10-20MAYNE PHARMA COMMERCIAL LLC$6Food and BeverageIn-kind items and services2025
2025-10-17Regeneron Healthcare Solutions, Inc.$34Travel and LodgingIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-10-16Arcutis Biotherapeutics, Inc.$19Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2025
2025-10-14Regeneron Healthcare Solutions, Inc.$37Food and BeverageIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-10-14MAYNE PHARMA COMMERCIAL LLC$1Food and BeverageIn-kind items and services2025
2025-10-13MAYNE PHARMA COMMERCIAL LLC$7Food and BeverageIn-kind items and services2025
2025-10-10Organon Llc$58Food and BeverageIn-kind items and servicesVTAMA Drug, Dermatology2025
2025-10-10Organon Llc$40Food and BeverageIn-kind items and servicesVTAMA Drug, Dermatology2025
2025-10-10Organon Llc$15Food and BeverageIn-kind items and servicesVTAMA Drug, Dermatology2025
2025-10-10Organon Llc$14Food and BeverageIn-kind items and servicesVTAMA Drug, Dermatology2025
2025-10-10Organon Llc$13Food and BeverageIn-kind items and servicesVTAMA Drug, Dermatology2025
2025-10-10Organon Llc$12Food and BeverageIn-kind items and servicesVTAMA Drug, Dermatology2025
2025-10-09Organon Llc$413Travel and LodgingIn-kind items and servicesVTAMA Drug, Dermatology2025
2025-10-09Organon Llc$383Travel and LodgingIn-kind items and servicesVTAMA Drug, Dermatology2025
2025-10-09Organon Llc$193Travel and LodgingIn-kind items and servicesVTAMA Drug, Dermatology2025
2025-10-09Arcutis Biotherapeutics, Inc.$8Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2025
2025-10-08PFIZER INC.$25Food and BeverageIn-kind items and servicesCIBINQO Drug, Inflammation & Immunology2025
2025-10-07GENZYME CORPORATION$28Food and BeverageIn-kind items and servicesDUPIXENT Biological, Immunology2025
2025-10-07MAYNE PHARMA COMMERCIAL LLC$0Food and BeverageIn-kind items and services2025
2025-10-06MAYNE PHARMA COMMERCIAL LLC$7Food and BeverageIn-kind items and services2025
2025-10-02Galderma Laboratories, L.P.$23Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-09-30Regeneron Healthcare Solutions, Inc.$5,551Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-09-30Regeneron Healthcare Solutions, Inc.$47Travel and LodgingIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-09-30Organon Llc$12Food and BeverageIn-kind items and services2025
2025-09-30MAYNE PHARMA COMMERCIAL LLC$0Food and BeverageIn-kind items and services2025
2025-09-29Regeneron Healthcare Solutions, Inc.$21Food and BeverageIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-09-29MAYNE PHARMA COMMERCIAL LLC$6Food and BeverageIn-kind items and services2025
2025-09-26Regeneron Healthcare Solutions, Inc.$119Food and BeverageIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-09-24GENZYME CORPORATION$23Food and BeverageIn-kind items and servicesDUPIXENT Biological, Immunology2025
2025-09-24ABBVIE INC.$20Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-09-24MAYNE PHARMA COMMERCIAL LLC$1Food and BeverageIn-kind items and services2025
2025-09-23Regeneron Healthcare Solutions, Inc.$5,551Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-09-23Regeneron Healthcare Solutions, Inc.$104Travel and LodgingIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-09-23Regeneron Healthcare Solutions, Inc.$21Food and BeverageIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-09-23Incyte Corporation$17Food and BeverageCash or cash equivalentOPZELURA Drug, Dermatology2025
2025-09-23Regeneron Healthcare Solutions, Inc.$5Travel and LodgingIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-09-22MAYNE PHARMA COMMERCIAL LLC$6Food and BeverageIn-kind items and services2025
2025-09-20Regeneron Healthcare Solutions, Inc.$35Food and BeverageIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-09-17ABBVIE INC.$150Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-09-17LNHC, Inc$16Food and BeverageIn-kind items and servicesZELSUVMI Drug, DERMATOLOGY2025
2025-09-16Ortho Dermatologics, a division of Bausch Health US, LLC$23Food and BeverageIn-kind items and servicesCabtreo Drug, Dermatology2025
2025-09-16PFIZER INC.$18Food and BeverageIn-kind items and servicesCIBINQO Drug, Inflammation & Immunology2025
2025-09-16Ortho Dermatologics, a division of Bausch Health US, LLC$2Food and BeverageIn-kind items and servicesCabtreo Drug, Dermatology2025
2025-09-15Incyte Corporation$26Food and BeverageCash or cash equivalentOPZELURA Drug, Dermatology2025
2025-09-08Incyte Corporation$800Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-09-08Incyte Corporation$339Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-09-08Incyte Corporation$160Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-09-08Incyte Corporation$31Food and BeverageCash or cash equivalentOPZELURA Drug, Dermatology2025
2025-09-03Arcutis Biotherapeutics, Inc.$16Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2025
2025-09-02Regeneron Healthcare Solutions, Inc.$35Food and BeverageIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-08-28Incyte Corporation$18Food and BeverageCash or cash equivalentOPZELURA Drug, Dermatology2025
2025-08-28Galderma Laboratories, L.P.$5Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-08-27GENZYME CORPORATION$28Food and BeverageIn-kind items and servicesDUPIXENT Biological, Immunology2025
2025-08-26Regeneron Healthcare Solutions, Inc.$7,259Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-08-26GENZYME CORPORATION$2,989Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDUPIXENT Biological, Immunology2025
2025-08-26MAYNE PHARMA COMMERCIAL LLC$1Food and BeverageIn-kind items and services2025
2025-08-25MAYNE PHARMA COMMERCIAL LLC$7Food and BeverageIn-kind items and services2025
2025-08-23Janssen Biotech, Inc.$1,750Consulting FeeCash or cash equivalentTREMFYA Drug, Immunology2025
2025-08-23Regeneron Healthcare Solutions, Inc.$36Food and BeverageIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-08-21GENZYME CORPORATION$2,989Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDUPIXENT Biological, Immunology2025
2025-08-21Janssen Biotech, Inc.$96Travel and LodgingCash or cash equivalentTREMFYA Drug, Immunology2025
2025-08-20GENZYME CORPORATION$26Food and BeverageIn-kind items and servicesDUPIXENT Biological, Immunology2025
2025-08-19LNHC, Inc$15Food and BeverageIn-kind items and servicesZELSUVMI Drug, DERMATOLOGY2025
2025-08-18Arcutis Biotherapeutics, Inc.$2,250Consulting FeeCash or cash equivalentZoryve Drug, Dermatology2025
2025-08-18Arcutis Biotherapeutics, Inc.$348Travel and LodgingCash or cash equivalentZoryve Drug, Dermatology2025
2025-08-14Galderma Laboratories, L.P.$10Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-08-14Arcutis Biotherapeutics, Inc.$7Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2025
2025-08-13Lilly USA, LLC$24Food and BeverageIn-kind items and servicesTALTZ Drug, Immunology2025
2025-08-13MAYNE PHARMA COMMERCIAL LLC$1Food and BeverageIn-kind items and services2025
2025-08-12Janssen Biotech, Inc.$139Food and BeverageIn-kind items and servicesTREMFYA Drug, Immunology2025
2025-08-12Krystal Biotech Inc$15Food and BeverageIn-kind items and servicesVYJUVEK Drug, DERMATOLOGY2025
2025-08-11Organon Llc$14Food and BeverageIn-kind items and services2025
2025-08-11MAYNE PHARMA COMMERCIAL LLC$7Food and BeverageIn-kind items and services2025
2025-08-07Incyte Corporation$3,375Consulting FeeCash or cash equivalent2025
2025-08-07Arcutis Biotherapeutics, Inc.$21Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2025
2025-08-06PFIZER INC.$3,425Consulting FeeCash or cash equivalentCIBINQO Drug, Inflammation & Immunology2025
2025-08-06Incyte Corporation$29Food and BeverageCash or cash equivalentOPZELURA Drug, Dermatology2025
2025-08-06Incyte Corporation$10Food and BeverageCash or cash equivalentOPZELURA Drug, Dermatology2025
2025-08-05Regeneron Healthcare Solutions, Inc.$32Food and BeverageIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-08-04Organon Llc$17Food and BeverageIn-kind items and services2025
2025-08-04MAYNE PHARMA COMMERCIAL LLC$7Food and BeverageIn-kind items and services2025
2025-08-04MAYNE PHARMA COMMERCIAL LLC$0Food and BeverageIn-kind items and services2025
2025-07-31Almirall LLC$19Food and BeverageIn-kind items and servicesKlisyri Drug, Dermatology2025
2025-07-31Galderma Laboratories, L.P.$12Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-07-29Incyte Corporation$20Food and BeverageCash or cash equivalentOPZELURA Drug, Dermatology2025
2025-07-29ABBVIE INC.$1Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-07-25GENZYME CORPORATION$6,384Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDUPIXENT Biological, Immunology2025
2025-07-25Regeneron Healthcare Solutions, Inc.$1,495Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-07-23Incyte Corporation$77Food and BeverageCash or cash equivalent2025
2025-07-23Arcutis Biotherapeutics, Inc.$75Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2025
2025-07-23PFIZER INC.$62Food and BeverageIn-kind items and servicesCIBINQO Drug, Inflammation & Immunology2025
2025-07-23Incyte Corporation$23Food and BeverageCash or cash equivalent2025
2025-07-22Regeneron Healthcare Solutions, Inc.$24Food and BeverageIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-07-22Cipher Pharmaceuticals US LLC$18Food and Beverage (2 payments)Cash or cash equivalentNatroba Drug, Antiparasitic2025
2025-07-22PFIZER INC.$7Food and BeverageIn-kind items and servicesCIBINQO Drug, Inflammation & Immunology2025
2025-07-21PFIZER INC.$15Food and BeverageIn-kind items and servicesCIBINQO Drug, Inflammation & Immunology2025
2025-07-21MAYNE PHARMA COMMERCIAL LLC$7Food and BeverageIn-kind items and services2025
2025-07-21MAYNE PHARMA COMMERCIAL LLC$1Food and BeverageIn-kind items and services2025
2025-07-17PFIZER INC.$22Food and BeverageIn-kind items and servicesCIBINQO Drug, Inflammation & Immunology2025
2025-07-17Ortho Dermatologics, a division of Bausch Health US, LLC$19Food and BeverageIn-kind items and servicesCabtreo Drug, Dermatology2025
2025-07-17Ortho Dermatologics, a division of Bausch Health US, LLC$8Food and BeverageIn-kind items and servicesCabtreo Drug, Dermatology2025
2025-07-17Galderma Laboratories, L.P.$6Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-07-16LNHC, Inc$18Food and BeverageIn-kind items and servicesZELSUVMI Drug, DERMATOLOGY2025
2025-07-15MAYNE PHARMA COMMERCIAL LLC$1Food and BeverageIn-kind items and services2025
2025-07-14GENZYME CORPORATION$27Food and BeverageIn-kind items and servicesDUPIXENT Biological, Immunology2025
2025-07-14MAYNE PHARMA COMMERCIAL LLC$7Food and BeverageIn-kind items and services2025
2025-07-14Ortho Dermatologics, a division of Bausch Health US, LLC$7Food and BeverageIn-kind items and servicesCabtreo Drug, Dermatology2025
2025-07-11Galderma Laboratories, L.P.$6Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-07-10GENZYME CORPORATION$132Food and BeverageIn-kind items and servicesDUPIXENT Biological, Immunology2025
2025-07-10Regeneron Healthcare Solutions, Inc.$21Food and BeverageIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-07-09Arcutis Biotherapeutics, Inc.$15Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2025
2025-07-03Arcutis Biotherapeutics, Inc.$8Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2025
2025-06-30PFIZER INC.$21Food and BeverageIn-kind items and servicesCIBINQO Drug, Inflammation & Immunology2025
2025-06-30Ortho Dermatologics, a division of Bausch Health US, LLC$9Food and BeverageIn-kind items and servicesCabtreo Drug, Dermatology2025
2025-06-30Ortho Dermatologics, a division of Bausch Health US, LLC$1Food and BeverageIn-kind items and servicesCabtreo Drug, Dermatology2025
2025-06-30Ortho Dermatologics, a division of Bausch Health US, LLC$1Food and BeverageIn-kind items and servicesCabtreo Drug, Dermatology2025
2025-06-27Regeneron Healthcare Solutions, Inc.$3,843Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-06-27Regeneron Healthcare Solutions, Inc.$42Travel and LodgingIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-06-27Regeneron Healthcare Solutions, Inc.$18Travel and LodgingIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-06-26Galderma Laboratories, L.P.$8Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-06-24Incyte Corporation$24Food and BeverageCash or cash equivalentOPZELURA Drug, Dermatology2025
2025-06-24MAYNE PHARMA COMMERCIAL LLC$0Food and BeverageIn-kind items and services2025
2025-06-23GENZYME CORPORATION$24Food and BeverageIn-kind items and servicesDUPIXENT Biological, Immunology2025
2025-06-23MAYNE PHARMA COMMERCIAL LLC$6Food and BeverageIn-kind items and services2025
2025-06-19Regeneron Healthcare Solutions, Inc.$26Food and BeverageIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-06-18ABBVIE INC.$28Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-06-18Incyte Corporation$4Food and BeverageCash or cash equivalentOPZELURA Drug, Dermatology2025
2025-06-16GENZYME CORPORATION$4,697Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDUPIXENT Biological, Immunology2025
2025-06-16GENZYME CORPORATION$13Travel and LodgingCash or cash equivalentDUPIXENT Biological, Immunology2025
2025-06-16Galderma Laboratories, L.P.$5Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-06-12Arcutis Biotherapeutics, Inc.$16Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2025
2025-06-11PFIZER INC.$29Food and BeverageIn-kind items and servicesCIBINQO Drug, Inflammation & Immunology2025
2025-06-10Regeneron Healthcare Solutions, Inc.$5,551Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-06-10MAYNE PHARMA COMMERCIAL LLC$0Food and BeverageIn-kind items and services2025
2025-06-09MAYNE PHARMA COMMERCIAL LLC$7Food and BeverageIn-kind items and services2025
2025-06-06Regeneron Healthcare Solutions, Inc.$124Food and BeverageIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-06-06Galderma Laboratories, L.P.$8Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-06-05GENZYME CORPORATION$7,259Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDUPIXENT Biological, Immunology2025
2025-06-05GENZYME CORPORATION$4,697Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDUPIXENT Biological, Immunology2025
2025-06-05GENZYME CORPORATION$236Travel and LodgingIn-kind items and servicesDUPIXENT Biological, Immunology2025
2025-06-05GENZYME CORPORATION$54Travel and LodgingCash or cash equivalentDUPIXENT Biological, Immunology2025
2025-06-05GENZYME CORPORATION$32Travel and LodgingCash or cash equivalentDUPIXENT Biological, Immunology2025
2025-06-05GENZYME CORPORATION$26Food and BeverageCash or cash equivalentDUPIXENT Biological, Immunology2025
2025-06-05Galderma Laboratories, L.P.$24Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-06-05GENZYME CORPORATION$20Food and BeverageCash or cash equivalentDUPIXENT Biological, Immunology2025
2025-06-04Regeneron Healthcare Solutions, Inc.$32Food and BeverageIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-06-04PFIZER INC.$24Food and BeverageIn-kind items and servicesCIBINQO Drug, Inflammation & Immunology2025
2025-06-03MAYNE PHARMA COMMERCIAL LLC$1Food and BeverageIn-kind items and services2025
2025-06-02Incyte Corporation$26Food and BeverageCash or cash equivalentOPZELURA Drug, Dermatology2025
2025-06-02MAYNE PHARMA COMMERCIAL LLC$8Food and BeverageIn-kind items and services2025
2025-05-29Galderma Laboratories, L.P.$141Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-05-29GENZYME CORPORATION$26Food and BeverageIn-kind items and servicesDUPIXENT Biological, Immunology2025
2025-05-22Arcutis Biotherapeutics, Inc.$8Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2025
2025-05-22PFIZER INC.$4Food and BeverageIn-kind items and servicesCIBINQO Drug, Inflammation & Immunology2025

The latest 200 records of 1,395.

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2025-12-19Incyte CorporationSTAT MEDICAL SERVICES$4,469A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo2025
2025-11-06Ferring Pharmaceuticals ASYale University$3,550A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene F2025
2025-10-29Incyte CorporationSTAT MEDICAL SERVICES$1,933A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo2025
2025-10-23Ferring Pharmaceuticals ASYale University$10,581A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene F2025
2025-09-23Incyte CorporationSTAT MEDICAL SERVICES$2,504A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo2025
2025-09-04Ferring Pharmaceuticals ASYale University$1,200A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene F2025
2025-09-04Ferring Pharmaceuticals ASYale University$1,800A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene F2025
2025-08-26Incyte CorporationSTAT MEDICAL SERVICES$5,024A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo2025
2025-08-14Incyte CorporationSTAT MEDICAL SERVICES$2,259A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo2025
2025-08-04Ferring Pharmaceuticals ASYale University$5,900A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene F2025
2025-07-25Ferring Pharmaceuticals ASYale University$1,450A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene F2025
2025-06-24Incyte CorporationSTAT MEDICAL SERVICES$7,331A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo2025
2025-06-05Ferring Pharmaceuticals ASYale University$30,000A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene F2025
2025-02-05Eli Lilly and CompanySUNRISE MEDICAL RESEARCH INC$21,074A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK2025
2025-01-29Incyte CorporationACRC TRIALS$12,000A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo2025
2024-12-18Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$1,000A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.052024
2024-12-18Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$385A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.052024
2024-12-02Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$1,968A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.052024
2024-12-02Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$3,000A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.052024
2024-08-03Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$73AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2024
2024-08-03Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$59AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2024
2024-08-03Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$73AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2024
2024-08-03Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$59AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2024
2024-08-03Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$59AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2024
2024-08-03Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$73AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2024
2024-08-03Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$57AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2024
2024-08-03Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$25AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2024
2024-08-03Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$59AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2024
2024-08-03Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$73AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2024
2024-08-03Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$59AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2024
2024-08-03Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$73AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2024
2024-08-03Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$59AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2024
2024-08-03Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$59AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2024
2024-08-03Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$73AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2024
2024-08-03Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$57AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2024
2024-08-03Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$25AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2024
2024-08-03Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$59AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2024
2024-07-23Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$2,000AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2024
2024-07-23Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$63AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2024
2024-07-23Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$73AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2024
2024-07-23Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$59AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2024
2024-07-23Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$59AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2024
2024-07-23Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$1,000AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2024
2024-07-23Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$1,358AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2024
2024-07-01SANOFI US SERVICES INC.Marwah Investments Cort$364Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD)2024
2024-02-05Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$357A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.052024
2024-01-17Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$1,201AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2024
2024-01-17Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$1,400AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2024
2024-01-09Eli Lilly and CompanySUNRISE MEDICAL RESEARCH INC$15,445A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK2024
2023-12-04Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$3,000A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.2023
2023-12-04Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$1,910A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.2023
2023-12-04Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$1,729A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.052023
2023-12-01SANOFI US SERVICES INC.Marwah Investments Cort$2,000Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD)2023
2023-12-01SANOFI US SERVICES INC.Marwah Investments Cort$780Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD)2023
2023-11-30Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$1,125AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2023
2023-11-30Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$1,125AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2023
2023-11-06Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$357A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.052023
2023-10-16Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$385A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.2023
2023-10-16Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$100A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.2023
2023-10-16Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$2,800A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.2023
2023-10-11Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$1,125AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2023
2023-10-11Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$1,400AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2023
2023-10-06Eli Lilly and CompanySUNRISE MEDICAL RESEARCH INC$12,963A PHASE 3 DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS (PK) OF 2023
2023-10-04Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$186A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.052023
2023-09-13Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$72A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN W2023
2023-09-13Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$19A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN W2023
2023-09-13Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$19A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN W2023
2023-09-13Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$80A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN W2023
2023-09-13Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$80A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN W2023
2023-09-13Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$72A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN W2023
2023-09-13Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$59A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN W2023
2023-09-13Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$59A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN W2023
2023-09-13Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$73A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN W2023
2023-09-13Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$73A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN W2023
2023-09-05Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$2,079A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.052023
2023-08-26Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$1,400AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2023
2023-08-10Eli Lilly and CompanyMarwah Investments Corporation$13,380A PHASE 3 DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS (PK) OF 2023
2023-06-26Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$4,096A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.2023
2023-06-13Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$1,125AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2023
2023-05-29Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$1,543A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.052023
2023-05-23Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$75A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 02023
2023-05-20Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$1,400AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2023
2023-05-16Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$1,650A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 02023
2023-05-01Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$3,894A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 02023
2023-05-01Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$1,915A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.052023
2023-04-20Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$200A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 02023
2023-04-20Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$1,000A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 02023
2023-04-20Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$3,150A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 02023
2023-04-20Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$1,540A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 02023
2023-04-14Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$488AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2023
2023-04-14Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$1,125AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2023
2023-04-14Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$1,125AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2023
2023-04-04SANOFI US SERVICES INC.Marwah Investments Cort$364Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD)2023
2023-04-03Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$1,850A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.2023
2023-04-03Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$814A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.052023
2023-04-03Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$3,000A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 02023
2023-04-03Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$3,000A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 02023
2023-02-27Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$1,810A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.2023
2023-02-27Arcutis Biotherapeutics, Inc.Marwah Investments Corporation dba ACRC Trials$7,495A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.2023
2023-02-17Dermavant Sciences, Inc.Marwah Investments Corporation dba ACRC Trials$1,086AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP2023

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Tarrant CountyGrapevine city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Grapevine, TX, county Tarrant County, TX, state Texas; placed by its city name.

MeasurePlace (city or town)
Grapevine, TX
County
Tarrant County, TX
State
Texas
Population B0100351,1392,167,39030,188,424
Population, 2020 census P150,6312,110,64029,145,505
Median age B0100239.735.235.6
Under 18 B0100121.3%25.4%25.0%
65 and over B0100114.1%12.3%13.4%
Households B1100121,593782,41910,992,816
Foreign born B0500217.2%17.2%17.6%
Median household income B19013$111,376$84,207$78,476
Median family income B19113$148,036$102,307$94,599
Per capita income B19301$61,797$42,755$40,752
Poverty rate B170016.7%11.1%13.8%
Unemployment rate B230254.7%4.7%5.3%
Civilian labor force B2302530,6431,156,00415,233,563
Mean commute (minutes) B0801322.326.826.7
Bachelor's degree or higher B1500357.5%34.8%33.8%
Housing units B2500122,885843,25712,128,515
Owner-occupied B2500352.7%59.3%62.6%
Renters B2500347.3%40.7%37.4%
Median home value B25077$493,100$323,900$283,800
Median gross rent B25064$1,863$1,547$1,403
White, not Hispanic B0300261.9%42.0%39.1%
Black B030024.4%17.3%11.9%
Hispanic or Latino B0300221.0%30.3%39.7%
Asian B030027.9%6.1%5.5%
American Indian and Alaska Native B030020.2%0.1%0.1%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Grapevine, TX.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.